BREAKWATER safety lead-in (SLI): Encorafenib plus cetuximab (EC) +/- chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC)

by on 16 de maig de 2022 with No hi ha comentaris
  • Kopetz, S., Yoshino, T., Kim, T. W., Desai, J., Yaeger, R., Van Cutsem, E., . . . Tabernero, J. (2022). BREAKWATER safety lead-in (SLI): Encorafenib plus cetuximab (EC) +/- chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF(V600E)) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 40(4), 134. https://doi.org/10.1200/JCO.2022.40.4_suppl.134 (Meeting abstract)

Deixa un comentari

L'adreça electrònica no es publicarà. Els camps necessaris estan marcats amb *